Latest Insider Transactions at Karuna Therapeutics, Inc. (KRTX)
This section provides a real-time view of insider transactions for Karuna Therapeutics, Inc. (KRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Karuna Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Karuna Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
42,604
-92.39%
|
$14,059,320
$330.0 P/Share
|
|
Mar 18
2024
|
William P Kane Jr Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,828
-68.08%
|
$4,563,240
$330.0 P/Share
|
|
Mar 18
2024
|
William Meury President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
29,379
-67.6%
|
$9,695,070
$330.0 P/Share
|
|
Mar 18
2024
|
Jason Parker Brown Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,167
-83.09%
|
$6,985,110
$330.0 P/Share
|
|
Mar 18
2024
|
Christopher J Coughlin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Steven M Paul |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
140,367
-100.0%
|
$46,321,110
$330.0 P/Share
|
|
Mar 18
2024
|
Steven M Paul |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,596
-59.65%
|
$3,496,680
$330.0 P/Share
|
|
Mar 18
2024
|
Andrew Craig Miller President of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
23,389
-79.88%
|
$7,718,370
$330.0 P/Share
|
|
Mar 18
2024
|
James Healy |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,381,149
-100.0%
|
$455,779,170
$330.0 P/Share
|
|
Mar 18
2024
|
James Healy |
SELL
Sale (or disposition) back to the issuer
|
Direct |
33,490
-98.52%
|
$11,051,700
$330.0 P/Share
|
|
Mar 18
2024
|
Jeffrey M Jonas |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Laurie J Olson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Atul Pande |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
Denice Torres |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 18
2024
|
David E. Wheadon |
SELL
Sale (or disposition) back to the issuer
|
Direct |
990
-100.0%
|
$326,700
$330.0 P/Share
|
|
Mar 08
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.26%
|
$1,590,000
$318.64 P/Share
|
|
Mar 08
2024
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+5.24%
|
$622,500
$83.02 P/Share
|
|
Mar 04
2024
|
Steven M Paul |
BUY
Bona fide gift
|
Indirect |
30,304
+50.0%
|
-
|
|
Mar 04
2024
|
Steven M Paul |
SELL
Bona fide gift
|
Indirect |
30,304
-92.76%
|
-
|
|
Mar 01
2024
|
Steven M Paul |
BUY
Bona fide gift
|
Indirect |
60,608
+49.06%
|
-
|
|
Mar 01
2024
|
Steven M Paul |
SELL
Bona fide gift
|
Indirect |
60,608
-59.05%
|
-
|
|
Feb 29
2024
|
Steven M Paul |
BUY
Other acquisition or disposition
|
Indirect |
47,378
+40.16%
|
$14,924,070
$315.18 P/Share
|
|
Feb 23
2024
|
Steven M Paul |
BUY
Exercise of conversion of derivative security
|
Direct |
31,518
+25.31%
|
$1,670,454
$53.5 P/Share
|
|
Feb 13
2024
|
Jason Parker Brown Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
278
-1.3%
|
$88,404
$318.0 P/Share
|
|
Feb 09
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,046
-2.54%
|
$331,582
$317.14 P/Share
|
|
Feb 09
2024
|
Andrew Craig Miller President of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
1,011
-4.14%
|
$320,487
$317.14 P/Share
|
|
Feb 09
2024
|
Steven M Paul |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-7.05%
|
$254,868
$317.14 P/Share
|
|
Feb 08
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.51%
|
$1,580,000
$316.3 P/Share
|
|
Feb 08
2024
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+7.75%
|
$435,000
$58.71 P/Share
|
|
Jan 08
2024
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-27.96%
|
$4,740,000
$316.81 P/Share
|
|
Jan 08
2024
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+10.72%
|
$1,452,500
$83.02 P/Share
|
|
Dec 28
2023
|
William Meury President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,694
-22.84%
|
$2,747,304
$316.3 P/Share
|
|
Dec 28
2023
|
William P Kane Jr Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,828
-21.68%
|
$1,209,648
$316.3 P/Share
|
|
Dec 08
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.72%
|
$2,020,000
$202.51 P/Share
|
|
Dec 08
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+12.14%
|
$850,000
$68.55 P/Share
|
|
Nov 08
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.71%
|
$885,000
$177.18 P/Share
|
|
Nov 08
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.19%
|
$510,000
$68.55 P/Share
|
|
Oct 09
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.15%
|
$865,000
$173.37 P/Share
|
|
Oct 09
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.79%
|
$510,000
$68.55 P/Share
|
|
Sep 29
2023
|
Jason Parker Brown Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,496
+17.33%
|
-
|
|
Sep 08
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.89%
|
$920,000
$184.46 P/Share
|
|
Sep 08
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+10.48%
|
$510,000
$68.55 P/Share
|
|
Sep 01
2023
|
Jeffrey M Jonas |
SELL
Open market or private sale
|
Direct |
13,809
-37.38%
|
$2,582,283
$187.73 P/Share
|
|
Sep 01
2023
|
Jeffrey M Jonas |
BUY
Exercise of conversion of derivative security
|
Direct |
13,809
+48.27%
|
$96,663
$7.27 P/Share
|
|
Aug 22
2023
|
Troy A. Ignelzi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-1.19%
|
$262,500
$175.18 P/Share
|
|
Aug 22
2023
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+4.48%
|
$13,500
$9.2 P/Share
|
|
Aug 08
2023
|
Stephen K. Brannan Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-5.65%
|
$900,000
$180.65 P/Share
|
|
Aug 08
2023
|
Stephen K. Brannan Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+11.28%
|
$510,000
$68.55 P/Share
|
|
Aug 01
2023
|
Jeffrey M Jonas |
SELL
Open market or private sale
|
Direct |
13,810
-39.41%
|
$2,706,760
$196.61 P/Share
|
|
Aug 01
2023
|
Jeffrey M Jonas |
BUY
Exercise of conversion of derivative security
|
Direct |
13,810
+48.27%
|
$96,670
$7.27 P/Share
|